Scientific Program - Neuroimmunology

Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here
Neuroimmunology Section Heads: Hans-Peter Hartung, Germany & Jacek Losy, Poland
Hall C
07:00-07:50 E-Poster Presentations
  Chairs: Maciej Jurynczyk, UK & Jan Lycke, Sweden
08:00-08:55 Can multiple sclerosis (MS) be reliably differentiated from isolated CNS lupus?
Systemic lupus erythematosus is a name indicater, a systematic disease, the manifestations of which are very heterogeneous. In some cases, the disease appears to be limited to the central nervous system in a presentation similar to that of MS, but requiring different therapies. Can the two be differentiated clinically?
08:00-08:10 Host: Iwona Kurkowska-Jastrzebaska, Poland
08:10-08:25 Yes: Alicja Kalinowska, Poland
08:25-08:40 No: Joab Chapman, Israel
08:40-08:55 Discussion and Rebuttals
Is the central vein sign (CVS) really helpful in differentiating MS from other white-matter diseases?
 Capsule:  MRI is a pivotal tool for the early and accurate diagnosis of MS. Yet, the current MRI criteria still lack perfect speciality and sensitvity. Recently, the CVS has been proposed as a new MRI marker which may improve the accuracy of diagnosing MS. However, the predictive value of the CVS for the development of clinical MS in patients at risk is still not clear. 
08:55-09:05 Host: Mark Freedman, Canada
09:05-09:20 Pro: Robert Zivadinov, USA
09:20-09:35 Con: Cris Constaniescu, UK
Discussion and Rebuttals
09:50-10:10  Coffee Break
  Chair: Andrzej Glabinski, Poland & Vitalie Lisnic, Moldova
10:10-11:10 All pathology in NMO is AQP4-IgG and complement dependent
NMO relapses are thought to involve AQP4-IgG binding to its target (AQP4) followed by complement activation. In vitro, elimination of complement markedly abrogates pathology and drugs that reduce complement activity are clinically effective. However, other pathologies are now being described in NMO, some of which do not result in necrosis or are not characterized by evidence of complement activation. The clinical significance of these pathologies is not fully defined.Is complement activation key to NMO pathology and what gains can be expected from complement inhibitors?
10:10-10:20 Host: Hans-Peter Hartung, Germany
10:20-10:35 Pro: Brian Weinshenker, USA
10:35-10:50 Con: Friedemann Paul, Germany
10:50-11:10 Discussion and Rebuttals
Young Investigator Scholarship Winners
11:10-11:25 Targeting key signaling factors as a way to control microglial activation and induction of neuroinflammation: Bogna Badyra, Poland
11:25-11:40 Characteristics of multiple sclerosis relapses and factors affecting relapses frequency in patients with immunodulatory therapy: Mrysolav Bozhenko, Ukraine
11:40-11:55 Progressive multiple sclerosis patients have a higher burden of autonomic dysfunction compared to relapsing remitting phenotype: Luka Crnosija, Croatia
Hydronamic hypothesis as an attempt to explain the Uththoff's phenomenon mechanism: Piotr Nogal, Poland
12:10-13:10 Industry Sponsored Symposium (Not for CME) - Hall A
13:10-13:55 Lunch Break & Meet the Expert sessions